NECLIFE — Nectar Lifesciences Balance Sheet
0.000.00%
- IN₹4.95bn
- IN₹10.98bn
- IN₹16.84bn
- 80
- 83
- 24
- 70
Annual balance sheet for Nectar Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 197 | 243 | 162 | 179 | 203 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,763 | 5,522 | 6,107 | 4,450 | 4,822 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 16,152 | 12,388 | 13,548 | 12,312 | 12,838 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8,607 | 8,322 | 7,652 | 6,904 | 6,561 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 26,333 | 23,881 | 23,908 | 21,892 | 21,911 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12,479 | 11,874 | 10,038 | 8,909 | 9,728 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 14,972 | 13,261 | 13,029 | 11,246 | 11,218 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11,361 | 10,620 | 10,879 | 10,646 | 10,692 |
Total Liabilities & Shareholders' Equity | 26,333 | 23,881 | 23,908 | 21,892 | 21,911 |
Total Common Shares Outstanding |